Project Grant R43CA298750
Award Date
4/15/25
Completion Date
3/31/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Sensewhy, Inc. (N7FTT2U8NHX7)
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $257,415 to develop and pilot test a scalable, AI-enhanced smartphone app-based intervention to support adolescent e-cigarette cessation. The project aims to create a cost-effective, personalized app that can be feasibly implemented in schools, clinics, and community settings. Key products and services include: Refining a smartphone app-based intervention with...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides funding to develop and test a novel, smartphone-based smoking cessation intervention that integrates olfactory stimulation to reduce cigarette cravings. The $279,573 award supports a two-phase research effort to refine the olfactory stimulation delivery system and evaluate its adjunctive benefits when integrated with a smartphone-based smoking...
This federal Project Grant award of $619,175 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research Program (CFDA 93.393) will support a hybrid effectiveness-implementation trial to evaluate a novel harm reduction approach for oncology outpatients who smoke but refuse traditional tobacco treatment. The study aims to directly compare rates of switching from cigarettes to e-cigarettes versus standard care in a sample of 208 oncology outpatients. The primary outcome...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will provide $885,824 to Health Research, Inc. over a period of 2 years beginning August 1, 2024 to explore consumer responses to newly authorized modified risk claims for smokeless tobacco products. The research aims to: 1) assess consumers' exposure and reactions to these modified risk claims, and 2) determine whether the claims influence consumer demand...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $316,873 to adapt a validated Spanish-language smoking cessation intervention into a smartphone app. The goals are to develop the "Libre del Cigarrillo" app (Aim 1) and conduct a pilot randomized controlled trial to evaluate its feasibility and acceptability compared to existing printed materials and standard-of-care texting program (Aim 2). The project aims to...
The National Cancer Institute (NCI) awarded a Project Grant under the federal Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Oklahoma Health Sciences Center in the amount of $625,201.00. The grant is for a randomized factorial trial to evaluate the combined effect of the smoking cessation medication varenicline with nicotine lozenges and a smartphone-based medication adherence intervention on smoking cessation outcomes. The 5-year study aims to enroll 496 adult...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to determine the cost-effectiveness of providing free nicotine replacement therapy (NRT) in combination with a smoking cessation smartphone app (iCanQuit) for Hispanic adults. The $757,913 award, with a performance period from February 1, 2025 to January 31, 2030, will fund a fully-powered randomized controlled trial to assess whether the...
This federal Project Grant award of $661,139, awarded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), will support a 6-year study to evaluate the use of oral nicotine pouches as a substitute for cigarette smoking among adult smokers in rural Appalachian counties. The study aims to test whether oral nicotine pouches can help reduce smoking-related cancer disparities in this high-risk population, compared to traditional nicotine replacement therapy. Over...
This federal Project Grant award from the National Cancer Institute (NCI) under the CFDA 93.393 Cancer Cause and Prevention Research program provides $1,226,040.00 to the Regents of the University of Minnesota to conduct a randomized clinical trial of a culturally-tailored suite of smoking cessation resources for American Indian persons. The project aims to co-create a culturally aligned Smokefree.gov website, test the efficacy of the Smokefree for Natives digital cessation resources through a...
The National Cancer Institute (NCI) awarded a $602,786 Project Grant under the CFDA 93.393 "Cancer Cause and Prevention Research" program to The Medical University of South Carolina (MUSC) to conduct a 12-week randomized controlled trial. The study aims to evaluate the efficacy of varenicline, an FDA-approved smoking cessation medication, combined with a psychosocial intervention, in treating the co-use of tobacco and cannabis among 200 adult participants in South Carolina. The study...